CMSC Live: 2024 Annual Meeting Day 3

EP: 1.CMSC Live: 2024 Annual Meeting Day 1

EP: 2.CMSC Live: 2024 Annual Meeting Day 2

Now Viewing

EP: 3.CMSC Live: 2024 Annual Meeting Day 3

Host

• Jeffrey Wilken, PhD
  President-Elect, Consortium of Multiple Sclerosis Centers (CMSC); assistant professor of neurology, Georgetown University; director of Research, Neuropsychology Associates of Fairfax; executive director, Washington Neuropsychology Research Group

Guests

• Marijean Buhse, PhD, RN, NP-C, MSCN
  Clinical Professor of Graduate Studies/Advanced Practice Nursing; Program Director, Doctor of Nursing Practice, Stony Brook School of Nursing
• Amy Sullivan, PsyD, ABPP
  Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Director, Neurological Institute Engagement and Well-being; Director of Behavioral Medicine & Research, Mellen Center for MS; Chair, Neurological Institute Engagement and Women’s Leadership Development Cleveland Clinic
• John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN
  Senior Vice President for Research and Training at Kessler Foundation; Professor in the Department of Physical Medicine & Rehabilitation and the Department of Neurology, Rutgers New Jersey Medical School

Segment Breakdown

• 00:00 – Marijean Buhse, PhD, RN, NP-C, MSCN, discusses her panel presentation on multidisciplinary NMOSD care, the need for better definition of patient-reported outcomes in MS, and her presentation on MS aging and the conversation about stopping disease-modifying therapy.
• 09:51 – Amy Sullivan, PsyD, ABPP, talks about the ability to reconnect with colleagues at CMSC, Francios Bethoux's talk on art as a therapeutci medicine in MS, her presentation on stress management tools in MS, empowering women in leadership roles in medicine, and the need to better address burnout among physicians.
• 00:00 – John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, speaks about being inducted into the 2024 class of Giants of MS, his symposium of addressing and defining fatigue in clinical care, the failure of pharmacotherapy for cognitive challenges in MS, and the lack of clinical application of cognitive rehabiliation tools despite the thorough and exisiting literature supporting its use.